Based on our experience with this patient, we recommend an endovascular approach for similar COVID-19 patients and suggest a prophylactic dose of Lovenox (40mg daily) post-operatively for 14 days.

Introduction {#sec1}
============

The Covid-19 pandemic has swept the nation and the whole planet in the past few months. Despite it being predominantly a respiratory illness, the vascular system is also impacted by the disease with reports of spontaneous arterial and venous thrombosis[@bib1], [@bib2], [@bib3], [@bib4]. Here we describe the case of an asymptomatic COVID-19 patient who was treated at our institution for a symptomatic inflammatory AAA (abdominal aortic aneurysm). The patient consented to the publication of these case details.

Case report {#sec1.1}
-----------

A 65-year-old Caucasian male presented to an outside institution with symptoms of lower abdominal pain radiating to his back. He had known chronic back pain, but in the past 4 days his pain had worsened, prompting him to go to the emergency room. There, a CTA (computed tomography angiogram) of the abdomen and pelvis ([figure 1](#fig1){ref-type="fig"} ) was obtained, showing a 5.3 cm inflammatory AAA. The patient was accepted to transfer to our facility. Per our hospital's protocol, he was tested for COVID-19 as soon as he arrived at the floor and his surgery was delayed by 24 hours until we obtained the results. The patient tested positive for COVID-19, though he did not have any respiratory symptoms nor any other of the typical symptoms usually associated with the disease.Figure 1Patient CTA (coronal and axial views) showing 5.3cm inflammatory AAA. Arrow pointing at halo around the aneurysm wall.

He underwent a successful percutaneous EVAR (endovascular aortic repair ([figure 2](#fig2){ref-type="fig"} ) on hospital day 2 in less than 30 hours from his admission. In order to reduce the thrombotic complications associated with COVID-19, he received a larger than usual dose of heparin intraoperatively and was discharged home on post-operative day 1 on subcutaneous Lovenox. His symptoms resolved after the procedure.Figure 2Intraoperative Angiogram showing successful EVAR and exclusion of aneurysm

Discussion {#sec2}
==========

COVID-19 has changed the way we approach all aspects of medicine, including vascular surgery. Despite the complete cessation of all elective cases from mid-March to mid-May due to COVID-19, vascular surgeons continued to provide care for patients with a plethora of urgent and emergent vascular conditions. Our patient presented with abdominal pain radiating to the back in the presence of a 5.3 cm AAA, requiring prompt evaluation and treatment.

At the beginning of the outbreak of COVID-19, we were still learning about the virus and its modes of transmission, so we wanted to limit staff exposure to bodily fluids and pulverized tissue from electrocautery. So, at our institution, we transitioned early on in the pandemic to performing mostly endovascular procedures. EVAR is usually a much faster procedure than open repair, in addition to being less risky and our procedure of choice in the setting of an inflammatory AAA. It also results in a much shorter length of stay when compared with open repair. Our reasoning was to reduce overall time in the operating room and in the hospital, thus limiting staff exposure. For these reasons, we elected to proceed with an endovascular repair. The procedure was carried with the least number of people in the room possible. The duration of the procedure was 40 mins and it was done totally percutaneous and under general anesthesia, decreasing the time of exposure to the virus for the entire OR team. He was also discharge home on post-operative day 1 further limiting his exposure to the team caring for him.

There are two reports in the literature about EVAR in ruptured AAA in COVID-19 positive patients but neither involved inflammatory AAA[@bib5] ^,^ [@bib6] . Our patient's D-Dimer levels were elevated (2.23 ug FEU/ml) as well as the CRP level which was mildly elevated (0.9 mg/dl). Although not previously described, we wonder whether the inflammation associated with this patient's AAA was due to the virus, as COVID-19 has been shown to cause inflammation in various other parts of the human body[@bib7] ^,^ [@bib8]. We encourage people to report on any inflammatory AAAs they have treated in COVID-19 patients to see if a relationship can be established.

There have been reports linking COVID-19 to arterial and venous thrombosis, some suggesting that the virus may cause excessive inflammation, platelet activation, endothelial dysfunction or stasis[@bib3]). Others have reported on complement-associated microvascular injuries leading to the thrombosis[@bib4]. In addition, Giacomelli et al. reported a case of acute thrombosis of a Dacron aortic prosthetic graft in a patient with severe COVID-19-related pneumonia. Iba et al, even suggested thromboembolic prophylaxis in all hospitalized patients with COVID-19^9^. Due to these reports, we elected to give the patient higher than usual doses of heparin intraoperatively and kept the activated clotting time (ACT) greater than 300 seconds during the case. In addition, we started him on subcutaneous Lovenox (40mg daily) that evening to continue for 14 days after his surgery. While more data is necessary to support the correlation between COVID-19 and arterial and venous thrombosis and the value of prophylactic anticoagulation, we felt that in the presence of multiple reports of increased clotting, it was prudent in this case to take steps to decrease the risk of limb thrombosis. Given the fact that the patient did not have a thrombotic event, and the higher risk for bleeding complications with the full dose we decided to go with the prophylactic dose. There is no data to support either choice or to help determine the duration of treatment.

Finally, another aspect to consider while dealing with symptomatic or ruptured AAA is health care worker's safety. These cases are typically emergently transferred to tertiary or quaternary referral centers such as ours, sometimes in the middle of the night. In the case of a ruptured aneurysm the patient would typically be transferred directly to the OR and everyone in the room would be required to wear the appropriate protective equipment including an N95 mask covered by a regular surgical mask, a face shield, and gown and gloves. Symptomatic aneurysms are however transferred to the surgical floor if stable. Asymptomatic patients are not routinely tested in most emergency rooms, possibly increasing the risk of exposure to the virus during such transfers. Our patient was not tested for COVID-19 at the institution where he presented due to lack of typical symptoms, but he tested positive once he arrived at our facility, where we routinely test patients undergoing procedures. Despite wearing a regular surgical mask and gloves when examining the patient before the test results came back, no face shields or N-95 masks were worn, allowing health care workers to potentially have been exposed. The lack of uniform testing across institutions suggests that special care needs to be taken care with emergently transferred patients, including, perhaps, new institutional policies to protect health care workers.

Conclusion {#sec3}
==========

Vascular surgeons continue to take care of urgent and emergent conditions during the COVID-19 pandemic, including symptomatic AAAs. In COVID-19 positive patients we recommend a total percutaneous endovascular approach when possible and suggest low dose anticoagulation postoperatively to decrease the risk of limb thrombosis. We also urge health care workers to treat urgent and emergent transfers as though positive and take all precautions necessary until a test result is available.

Uncited reference {#sec4}
=================

[@bib9].
